Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Type 2 diabetes mellitus and coronary artery disease: features of perfusion volume computed tomography of the heart in a pharmacological test with adenosine triphosphate].

Terapevticheskii arkhiv·2023
Same author

[Safety and Effectiveness of Volumetric Computed Tomography of the Heart in Combination with a PharmacologicaTest with Adenosine Triphosphate in the Diagnosis of Coronary Heart Disease].

Kardiologiia·2021
Same author

[The study of myocardial perfusion by cardiac volumetric computed tomography, combined with adenosine triphosphate test, in a patient with painless myocardial ischemia and atherosclerosis of the coronary arteries].

Terapevticheskii arkhiv·2020
Same author

The periprocedural myocardial damage prevention during elective percutaneous coronary intervention as a result of pharmacological preconditioning with an oral form of nicorandil in patients with stable coronary artery disease. Pilot study.

Terapevticheskii arkhiv·2019
Same author

[Present-day possibilities of non-invasive control over microcirculation and metabolism in man].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2018
Same author

Vibrational spectra of DNA in the confined interglobular volume of photonic crystal.

Journal of biological physics·2018

Related Experiment Video

Updated: Mar 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

[Nonplatelet Effects of Ticagrelor].

V V Boiko1, G N Soboleva1

  • 1Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Complex, Moscow, Russia.

Kardiologiia
|March 15, 2017
PubMed
Summary

Ticagrelor, a P2Y12 receptor antagonist, boosts adenosine levels, potentially enhancing its therapeutic effects beyond platelet inhibition. This review explores ticagrelor's broader impact on cardiovascular and inflammatory processes.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Immunology

Background:

  • Ticagrelor is a P2Y12 receptor antagonist widely used in cardiovascular disease.
  • Its primary mechanism involves inhibiting platelet aggregation.
  • Emerging evidence suggests non-antiplatelet effects that warrant further investigation.

Purpose of the Study:

  • To review the current knowledge on the nonplatelet effects of ticagrelor.
  • To explore the role of adenosine in mediating ticagrelor's actions.
  • To compare ticagrelor's clinical profile with adenosine's pharmacological effects.

Main Methods:

  • Literature review of experimental and clinical studies.
  • Analysis of data on plasma adenosine concentrations.
  • Comparative discussion of ticagrelor's effects and adenosine's known actions.
Keywords:
adenosinenonplatelet effects of ticagrelorticagrelor

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Related Experiment Videos

Last Updated: Mar 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Main Results:

  • Ticagrelor demonstrably increases plasma adenosine concentrations.
  • Adenosine is a potential mediator of ticagrelor's additional therapeutic effects.
  • Ticagrelor influences vascular tone, cardiac electrophysiology, ischemia/reperfusion injury, immunity, and inflammation.

Conclusions:

  • Ticagrelor possesses significant nonplatelet effects, partly mediated by increased adenosine.
  • Understanding these effects provides a broader perspective on ticagrelor's clinical utility.
  • Further research into these mechanisms could reveal new therapeutic applications.